Ertugliflozin pidolate Drug Asset Due Diligence Report 2026

This Ertugliflozin pidolate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Ertugliflozin pidolate can convert its Small molecule drug profile and SGLT2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Ertugliflozin pidolate (query alias: ertugliflozin)
Modality / target	Small molecule drug; SGLT2; SGLT2 inhibitors
Highest global status	Approved
Originator	Pfizer Inc.
Active developers	Pfizer Inc., Merck Sharp & Dohme Corp., Merck Canada, Inc.

The MCP disease footprint includes Diabetes Mellitus, Type 2, Chronic heart failure. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07621380	Phase 4	Not yet recruiting	476	Percent change in NT-proBNP from baseline
CTR20262515	Not Applicable	进行中（尚未招募）	24	Not disclosed
CTR20261985	Not Applicable	进行中（招募完成）	24	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Ertugliflozin: Cardioprotective Effects on Epicardial Fat

Early Phase 1; n=61; evaluation: not stated. Reported fields: -; -; Basal(Mean) = 105 µmol/L/hr (Standard Deviation, 10)

DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes

Phase 4; n=41; evaluation: not stated. Reported fields: SBP(Mean) = 125 mmHg (Standard Deviation, 8.3); -; SBP(Mean) = 121 mmHg (Standard Deviation, 8.5)

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in Pediatric Participants (Ages 10 to 17 Years, Inclusive) With Type 2 Diabetes Mellitus

Phase 3; n=166; evaluation: not stated. Reported fields: Change From Baseline in Hemoglobin A1C (HbA1C) at Week 24 (Combined Ertugliflozin Versus Placebo)(Least Squares Mean) = 0.12 A1C Percentage (95% Confidence Interval, -0.23 to 0.47); Change From Baseline in Hemoglobin A1C (HbA1C) at Week 24 (Combined Ertugliflozin Versus Placebo)(Least Squares Mean): Difference in Bayesian Means = -0.67(95% CI, -1.06 to -0.29); Change From Baseline in Hemoglobin A1C (HbA1C) at Week 24 (Combined Ertugliflozin Versus Placebo)(Least Squares Mean): Difference in Bayesian Means = -0.67(95% CI, -1.06 to -0.29)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Ertugliflozin pidolate addresses Diabetes Mellitus, Type 2, Chronic heart failure. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2013-04-29	Merck & Co., Inc. and Pfizer Enter Worldwide Collaboration Agreement to Develop and Commercialize Ertugliflozin, an Investigational Medicine for Type 2 Diabetes	Approved	US$60.0M upfront

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “An oral liquid pharmaceutical composition of ertugliflozin”. The milestone feed surfaced a patent-application signal described as “Crystalline forms of ertugliflozin”. The milestone feed surfaced a patent-application signal described as “Medical use of combination of endothelin a (ETA) receptor antagonist and SGLT-2 inhibitor”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO